50 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Neolignans from the Arils of Myristica fragrans as Potent Antagonists of CC Chemokine Receptor 3.
Kindai University
Rodent selectivity of piperidine-4-yl-1H-indoles, a series of CC chemokine receptor-3 (CCR3) antagonists: insights from a receptor model.
Boehringer Ingelheim Pharma
Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H1 antagonists. Part I.
Astrazeneca
Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H1 antagonists. Part II: optimising in vivo clearance.
Astrazeneca
Discovery and lead optimization of a novel series of CC chemokine receptor 1 (CCR1)-selective piperidine antagonists via parallel synthesis.
Bristol-Myers Squibb
Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.
Astrazeneca
Discovery and structure-activity relationships of urea derivatives as potent and novel CCR3 antagonists.
Toray Industries
Design and synthesis of 6-fluoro-2-naphthyl derivatives as novel CCR3 antagonists with reduced CYP2D6 inhibition.
Astellas Pharma
Synthesis and structure-activity relationships of N-{1-[(6-fluoro-2-naphthyl)methyl]piperidin-4-yl}benzamide derivatives as novel CCR3 antagonists.
Astellas Pharma
From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part I: the discovery of CCR3 antagonist development candidate BMS-639623 with picomolar inhibition potency against eosinophil chemotaxis.
Bristol-Myers Squibb
Novel CCR1 antagonists with oral activity in the mouse collagen induced arthritis.
Novartis Institutes For Biomedical Research
Design and synthesis of a library of chemokine antagonists.
Novartis Institutes Of Biomedical Research
Discovery, optimization, and pharmacological characterization of novel heteroaroylphenylureas antagonists of C-C chemokine ligand 2 function.
Telik
Synthesis, biological evaluation, and metabolic stability of acrylamide derivatives as novel CCR3 antagonists.
Astellas Pharma
Discovery of trisubstituted cyclohexanes as potent CC chemokine receptor 2 (CCR2) antagonists.
Bristol-Myers Squibb
Discovery of a potent, selective and orally bioavailable 3,9-diazaspiro[5.5]undeca-2-one CCR5 antagonist.
Roche Palo Alto
Urea based CCR3 antagonists employing a tetrahydro-1,3-oxazin-2-one spacer.
Bristol-Myers Squibb
From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part II: Acyclic replacements for the (3S)-3-benzylpiperidine in a series of potent CCR3 antagonists.
Bristol-Myers Squibb
Capped diaminopropionamide-glycine dipeptides are inhibitors of CC chemokine receptor 2 (CCR2).
Bristol-Myers Squibb
CC chemokine receptor-3 (CCR3) antagonists: improving the selectivity of DPC168 by reducing central ring lipophilicity.
Bristol-Myers Squibb Pharmaceutical Research Institute
2,4-Disubstituted piperidines as selective CC chemokine receptor 3 (CCR3) antagonists: synthesis and selectivity.
Bristol-Myers Squibb Pharmaceutical Research Institute
Discovery of 3,5-bis(trifluoromethyl)benzyl L-arylglycinamide based potent CCR2 antagonists.
Merck Research Laboratories
Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety.
Takeda Pharmaceutical
The synthesis of substituted bipiperidine amide compounds as CCR3 ligands: antagonists versus agonists.
Schering-Plough Research Institute
Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency.
Pharmaceutical Research Institute
Novel ligands for the chemokine receptor-3 (CCR3): a receptor-modeling study based on 5D-QSAR.
Biographics Laboratory 3R
The synthesis of substituted bipiperidine amide compounds as CCR3 antagonists.
Schering-Plough Research Institute
N-Arylalkylpiperidine urea derivatives as CC chemokine receptor-3 (CCR3) antagonists.
Dbristol-Myers Squibb
Pyrrolidinohydroquinazolines--a novel class of CCR3 modulators.
Boehringer Ingelheim Pharma Gmbh And
Discovery of N-propylurea 3-benzylpiperidines as selective CC chemokine receptor-3 (CCR3) antagonists.
Bristol-Myers Squibb Pharmaceutical Research Institute
Discovery and structure-activity relationship of N-(ureidoalkyl)-benzyl-piperidines as potent small molecule CC chemokine receptor-3 (CCR3) antagonists.
Bristol-Myers Squibb
CCR3 antagonists: a potential new therapy for the treatment of asthma. Discovery and structure-activity relationships.
Bristol-Myers Squibb
Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection.
Merck Research Laboratories
Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection.
Merck Research Laboratories
Discovery of potent and selective phenylalanine derived CCR3 receptor antagonists. Part 2.
Smithkline Beecham Pharmaceuticals
Discovery of potent and selective phenylalanine derived CCR3 antagonists. Part 1.
Smithkline Beecham Pharmaceuticals
Design, synthesis, and discovery of a novel CCR1 antagonist.
Banyu Tsukuba Research Institute In Collaboration With Merck Research Laboratories
Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-Aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes.
Merck Research Laboratories
Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety.
Takeda Chemical Industries